12-05-2025
Venture Capital, IPOs, Licensing Deals, Collaborations, and M&A Transactions
The CAR-T industry is booming, with a significant surge in funding driven by successful therapies hitting the market. Over 170 companies are actively developing CAR-T products, with 1,944 therapies in stages of development and 110 collaborations valued up to approximately $67.9 billion. Since 2014, 89 companies secured $7.7 billion in venture capital, while 42 IPOs raised $6.4 billion. Despite a slowdown in M&A deals in 2024, over $141.2 billion has been raised through various transactions, potentially totaling $281.7 billion with undisclosed deals. The global landscape features 13 approved CAR-T therapies primarily targeting blood cancers, with ongoing clinical trials aiming to treat solid tumors as well.
Dublin, May 12, 2025 (GLOBE NEWSWIRE) -- The "CAR-T Funding Report - Venture Capital, IPOs, Licensing Deals, Collaborations, and M&A Transactions, 2025" report has been added to offering.
In recent years, the CAR-T industry has experienced a remarkable surge in funding. At first, the trend was subtle, but the tide has swelled as CAR-T therapies have reached the marketplace and created a funding boom. Today, CAR-T start-ups are being richly funded by investors and large pharma who are eager to get into this trending area of regenerative medicine.
Worldwide, more than 170 companies are now developing CAR-T products and therapies, with a total of 1,944 early and late-stage therapies in development. These companies have also entered into 110 collaboration agreements aimed at advancing various CAR-T candidates. Of these, only 38 have disclosed the value of their deals, which amounts to $23.58 billion. If we estimate the value of the undisclosed deals, the total value of these 110 collaborations is likely to reach approximately $67.9 billion.
The clinical successes of CAR-T therapies have sparked significant interest from venture capitalists globally. This increased activity has fueled advancements in CAR-T technology and the development of applications for both hematological cancers and other types of cancer. Since 2014, a total of 89 CAR-T companies have secured $7.7 billion in venture capital, enabling them to strengthen their foundations. Venture capital funding has remained strong and consistent throughout the development of the CAR-T industry.
Data shows that Initial Public Offerings (IPOs) within the CAR-T space were relatively slow last year. In 2024, only Kyverna Therapeutics went public, raising $319 million to support its anti-CD19 CAR-T therapies. However, from 2014 to present, 42 CAR-T companies have gone public, collectively raising $6.4 billion to further enhance their technology platforms, clinical trials, and corporate strategies.
Within this rapidly evolving industry, there are currently 72,418 patent records and 452 granted patents. As a result, large pharmaceutical companies are increasingly seeking to enter the CAR-T market by licensing patents from existing patent holders. Over the past decade, 91 CAR-T licensing deals have been valued at $6.3 billion, and this figure is expected to grow significantly over the next ten years.
While 2023 saw a resurgence in dealmaking, the CAR-T industry experienced a slowdown in mergers and acquisitions (M&A) in 2024, with only two deals completed. Although major M&A activity may not return in 2025, further deals are likely as large pharmaceutical companies look to deploy their cash reserves. Over the past decade, M&A deals have accounted for the largest share of CAR-T industry financing, totaling an impressive $97.4 billion.
In total, the CAR-T industry has raised more than $141.2 billion through various deal types, including IPOs, licensing deals, collaborations, and M&A transactions. It's important to note that the values of 61 out of 91 licensing deals, 75 out of 110 collaboration deals, and 12 out of 29 M&A deals remain undisclosed. If we estimate the value of these undisclosed transactions, the overall total is likely to reach a staggering $281.7 billion.
Globally Approved CAR-T Therapies
Since 2017, 13 CAR-T cell therapies have reached commercialization across multiple healthcare markets. Seven therapies have been approved by the U.S. FDA, after which approvals for them were issued in other major healthcare markets as well. Beyond the U.S., four CAR-T therapies-Relma-cel, Fucaso, Yuanruida, and Zever-cel - have been approved by China's National Medical Products Administration (NMPA). Additionally, two therapies, NexCAR19 and Qartemi, have received approval from India's Central Drugs Standard Control Organisation (CDSCO).
All 13 approved CAR-T cell therapies are currently used exclusively to treat blood cancers, which account for less than 5% of cancer patients worldwide. Today, there are approximately 1,944 ongoing clinical trials focused on addressing both blood cancers and solid tumors. Of these, only 244 trials are targeting solid cancers. This swell of clinical trials has been driven by the remarkable 90% remission rate achieved by most of the approved CAR-T therapies.
CAR-T Market Overview
To track funding within this rapidly growing industry, the publisher has released this 220-page CAR-T market funding report. It summarizes all types of investments flowing into CAR-T companies worldwide, including financing rounds, IPOs, M&A transactions, co-development agreements, and strategic partnerships. Additionally, it profiles 78 leading competitors who have been involved with these CAR-T industry funding events.
This report reveals the following information for the CAR-T Cell Therapy Industry:
Financing Rounds
IPOs
Asset Agreements
Strategic Partnerships
Co-Development Agreements
M&A Transactions
Companies Profiles for CAR-T Market Competitors
You can use it to:
Quantify CAR-T industry investments
Identify well-capitalized companies
Scout potential partnerships and alliances
Understand partnerships and co-development programs for CAR-T technologies
Identify M&A activity within the CAR-T industry
To summarize, CAR-T companies - from emerging start-ups to billion-dollar enterprises - have completed hundreds of billions of dollars in financial transactions in recent years. These companies are rapidly expanding across global healthcare markets.
This report delivers essential insights into the financial forces driving the industry, revealing where capital is flowing and how you can strategically position yourself to benefit from these trends.
Key Topics Covered:
1. EXECUTIVE SUMMARY
Globally-Approved CAR-T Cell Therapies
2. UPTAKE OF CAR-T THERAPIES, FULL YEAR 2017 to 2024
Number of Patients Treated with CAR-T Cell Therapies, Full Year 2017 to 2024
Sales Revenues Generated by FDA-Approved CAR-T Therapies, Full Year 2017-2024 .
List Prices of U.S. FDA-Approved CAR-T Therapies
3. CAR-T FUNDING: AN OVERVIEW
Venture Capital Raised by CAR-T Companies
Bellicum Pharmaceuticals
CRISPR Therapeutics
Autolus
Cellular Biomedicine Group
Adicet Bio
Autolus Limited
Cellular Biomedicine Group
Carina Biotech
PeproMene Bio
Precision BioSciences
Cabaletta Bio
Vor Biopharma
Gracel Biotechnologies
Mustang Bio
Poseida Therapeutics
BioNTech
Adicet Bio
Kyverna Therapeutics
EXUMA Biotech
IASO Biotherapeutics
Legend Biotech
JW Therapeutics
Vor Pharma
ImmPACT Bio
Synthekine
Gracell Biotechnologies
CARsgen Therapeutics
Umoja Biopharema
Juventas Cell Therapy
Celyad Oncology
Artiva Biotherapeutics
Caribou Biosciences
Biosceptre
Noile-Immune Biotech
Arcellx
Cellares Corporation
Interius BioTherapeutics
Synthekine
Umoja Biopharma
Wugen
Mnemo Therapeutics
AvenCell
Currus Biologics
Juventas Cell Therapy
Carina Biotech
IASO Biotherapeutics
Cellular Biomedicines
AffyImmune Therapeutics
Leucid Bio
Clade Therapeutics
SOTIO Biotech
EXUMA Biotech
ImmPACT Bio
Kyverna Therapeutics
Ucello Therapeutics
Mustang Bio
Wugen
Inceptor Bio
Tessa Therapeutics
Immuneel Therapeutics
OriCell Therapeutics
Carina Biotech
Juventas Cell Therapy
Arsenal Biosciences
Synthekine
IASO Biotherapeutics
MPC Therapeutics
OriCell Therapeutics
Verismo Therapeutics
Cargo Therapeutics
OneChain Immunotherapeutics
Caribou Biosciences
Verismo Therapeutics
Kyverna Therapeutics
Gracell Biotechnologies
Cellares
Celyad Oncology
Capstan Therapeutics
Limula
Cargo Therapeutics
Leman Biotech
Immuneel Therapeutics
Dynamic Cell Therapies
Arsenal Biosciences
AvenCell Therapeutics
March Biosciences
A2 Biotherapeutics
Umoja Biopharma
4. IPO FUNDING INVESTED IN CAR-T COMPANIES (42 IPOs)
Descriptions of IPO Funds Raised by CAR-T Companies, Jan. 2014 to Feb. 2025
Juno Therapeutics
Cellular Biomedicine Group
Xenetic Biosciences
Cellular Biomedicine Group
Autolus Therapeutics
Allogene Therapeutics
Precision BioSciences
Atara Biotherapeutics
Xenetic Biosciences
Cabaletta Bio
Atara Biotherapeutics
Legend Biotech
Mustang Bio
JW Therapeutics
Atara Biotherapeutics
Gracell Biotechnologies
Vor Biopharma
Adicet Bio
CARsgen Therapeutics
Xenetic Biosciences
Caribou Biosciences
Celyad Oncology
Adicet Bio
Legend Biotech
Kyverna Therapeutics
Arcellx
TC Biopharm
Celularity
TC BioPharm
Precision Biosciences
Legend Biotech
TC Biopharm
Vor Biopharma
Precigen
TC Biopharm
Celularity
Legend Biotech
Coeptis Therapeutics
Caribou Biosciences
Cargo Therapeutics
Kyverna Therapeutics
Mustang Bio
5. CAR-T LICENSING DEALS (90 Total)
CAR-T Licensing Deals & Values, January 2015 to February 2025
Cellectis & Ohio State University
bluebird bio & Five Prime Therapeutics
Poseida Therapeutics & Janssen Biotech
bluebird bio & ViroMed
Bellicum Pharmaceuticals & Astellas Pharma
CRISPR Therapeutics & MaxCyte
bluebird bio & Novartis
Novartis & Celyad
TC Biopharm & University College London (UCL)
Mustang Bio & Fred Hutchinson Cancer Research Center
Mustang Bio & Harvard University
bluebird bio & TC Biopharm
Janssen Biotech & Legend Biotech
Autolus & UCL Business
Otsuka Pharmaceutical & Osaka University
Cellular Biomedicine & Novartis
CRISPR Therapeutics & MaxCyte
Wugen & Washington University
Atara Biotherapeutics & Memorial Sloan Kettering Cancer Center
bluebird bio & Inhibrx
Autolus Therapeutics & Noile-Immune Biotech
Vor Biopharma & MaxCyte
Juno Therapeutics & Oxford Biomedica
Allogene Therapeutics & MaxCyte
Kite & Teneobio
Legend Biotech & Noile-Immune Biotech
Caribou Biosciences & MaxCyte
Prescient Therapeutics & University of Pennsylvania
Minerva Biotechnologies & Memorial Sloan Kettering Cancer Center
Luminary Therapeutics & Case Western Reserve University
Beam Therapeutics & Oxford Biomedica
SOTIO Biotech & Unum Therapeutics
Vor Biopharma & Metagenomi
Chimeric Therapeutics & City of Hope
Vor Biopharma & Arbor Biotechnologies
Immuneel Therapeutics & Hospital Clinic de Barcelona (HCB)
Vor Biopharma & National Cancer Institute (NCI)
Caribou Biosciences & Memorial Sloan Kettering Cancer Center
Carina Biotech & Bionomics
Atara Biotherapeutics & Bayer
Cellectis & SIRION Biotech
Eli Lilly & Precision BioSciences
AbbVie & Caribou Biosciences
Luminary Therapeutics & Bio-Techne Corporation
Wugen & HCW Biologics
Alpha Biopharma & Wugen
Servier & Precision Biosciences
Dr. Reddy's Laboratories & Pregene Biopharma
Celularity & MaxCyte
BioNTech & Takara Bio
Bellicum Pharmaceuticals & UNC Lineberger
Mustang Bio & Mayo Clinic
Precision Biosciences & Tiziana Sciences
Arcellx & Oxford Biomedica
Carina Biotech & BayPAT
Inceptor Bio & University of California
Rebirthel & Otsuka Pharmaceutical
Kyverna Therapeutics & National Institutes of Health (NIH)
Intellia Therapeutics & Kyverna Therapeutics
Antion Biosciences & Allogene Therapeutics
Sana Biotechnology & IASO Biotherapeutics
CellPoint & Pregene
Xenetic Biosciences
GO Therapeutics
LG Chem & MaxCyte
Roche & Poseida Therapeutics
Chugai Pharmaceutical & Noile-Immune Biotech
Beam Therapeutics & Orbital Therapeutics
Undisclosed Company & Oxford Biomedica
Coeptis Therapeutics & University of Pittsburgh
Cabaletta Bio & IASO Biotherapeutics
Inceptor Bio & Avectas
Kite Pharma & Refuge Biotechnologies
Kite Pharma & Arcellx
Cabaletta Bio & Autolus Therapeutics
Precigen & Alaunos
Leucid Bio & ImaginAb
Affini-T Therapeutics & MSK
Shunxi Holding & Cartherics
Janssen Biotech & Cellular Biomedicine
Astellas Pharma & Poseida Therapeutics
Imugene & Precision Biosciences
Cabaleta Bio & Oxford Biomedica
Kyverna Therapeutics & Oxford Biomedica
Coeptis Therapeutics & Univerdity of Pittsburgh
Janssen Biotech & Cellular Biomedicine Group
Legend Biotech & Novartis Pharma
AbbVie & Umoja Biopharma
Astellas Pharma & Kelonia Therapeutics
Allogene Therapeutics & Arbor Biotechnologies
6. CAR-T COLLABORATION DEALS (110 Total)
CAR-T Collaboration Deals between January 2013 and February 2025
bluebird Bio & Celgene Corporation
Pfizer, Inc. & Cellectis
Amgen & Kite Pharma
Five Prime Therapeutics & bluebird bio
Celgene & Juno Therapeutics
Cellectis & Servier
Kite Pharma & Cell Design Labs
Kite Pharma & Fosun Pharma
Cellular Biomedicine Group & GE Healthcare Life Sciences, China
Novartis & bluebird bio & Celyad
Mustang Bio & Harvard University & Beth Israel Deaconess Center
Jenssen Biotech & Legend Biotech
PersonGen & Anke Cellular Therapeutics & Miltenyi Biotec
Kite Pharma & Sangamo Therapeutics
bluebird bio & Celgene Corporation
AbbVie & Calibr
Novartis & Fraunhofer IZI
Cellular Biomedicine & Novartis
Regeneron Pharmaceuticals & bluebird bio
Cartherics & ToolGen
TC Biopharm & Dublin's Trinity College
MaxCyte & Kite Pharma
Phanes Therapeutics & Phanes Biopharmaceuticals & Fosun Kite
Cellectis SA & Servier Monde
MaxCyte & Allogene Therapeutics
Fate Therapeutics & Janssen Biotech
bluebird bio & Bristol Myers Squibb
Xenetic Biosciences & PJSC Pharmsynthez
Fate Therapeutics & Baylor College of Medicine
Beam Therapeutics & Oxford Biomedica
Carina Biotech & Glytherix
Chimeric Therapeutics & City of Hope
Biosceptre & Carina Biotech
Allogene Tx & University of Texas MD Anderson Cancer Center
Oxford Biomedica & PhoreMost Limited
Carina Biotech & Bionomics
Bayer AG & Atara Biotherapeutics
Oncternal Therapeutics & Karolinska Instituet
EXUMA Biotech & Moffitt Cancer Center
AbbVie & Caribou Biosciences
Cytovia Therapeutics & Cellectis SAS
JW Therapeutics & Thermo Fisher Scientific
AbbVie & Caribou Biosciences
Wugen & Alpha Biopharma
Dr. Reddy's Laboratories & Shenzhen Pregene Biopharma
Vor Biopharma & Abound Bio
Kite Pharma & Fosun Pharmaceutical
Takara Bio & BioNTech
Vor Biopharma & Janssen Biotech
Imugene & Celularity
Gracell Biotechnologies & FutureGen Biopharm
AdAlta & Carina Biotech
Celularity & Oncternal Therapeutics
Autolus Therapeutics & Blackstone Life Sciences
4basebio & Leucid Bio
Leucid Bio & Lonza
Oxford Biomedica & Arcellx
Carina Biotech & Bayerische Patentallianz (BayPAT)
Intellia Therapeutics & Kyverna Therapeutics
Arsenal Biosciences & Bristol Myers Squibb
Allogene Therapeutics & Antion Biosciences
Transgene & PersonGen BioTherapeutics
Immatics & Bristol Myers Squibb
Legend Biotech & Janssen Biotech
Umoja Biopharma & Lupagen
Immatics & Celgene
Immatics & Bristol Myers Squibb
Umoja Biopharma & TreeFrog Therapeutics
Invectys & University of Texas Cancer Center
Poseida Therapeutics & Roche
Chugai Pharmaceutical & Noile-Immune Biotech
Kite Pharma & Arcellx
Arsenal Biosciences & Genentech
Autolus Therapeutics & Bristol Myers Squibb
Inceptor Bio & Avectos
JW Therapeutics & 2seventy bio
Peter MacCallum Cancer Centre and Cartherics
Umoja Biopharma & IASO Biotherapeutics
Kite Pharma & Arcellx
Ori Biotech & Inceptor Bio
Simnova & Orna Therapeutics
CARsgen Therapeutics & Huadong Medicine
TC Biopharm & University of Texas MD Anderson Cancer Center
Kite Pharma & Arcellx
Peter MacCallum Cancer Centre & Cartherics
Cartherics & Shunxi Holding Group
Autolus Therapeutics & Cardinal Health
Cartherics & Shunxi
Janssen Biotech & Cellular Biomedicine
CytoMed & University of Texas MD Anderson Cancer Center
Noile-Immune Biotech & Sysmex
GenScript Biotech & T-MAXIMUM Biotech
CytoMed Therapeutics & Hangzhou CNK Therapeutics
CARsgen Therapeutics & Moderna
Cellares & Bristol Myers Squibb
Celularity & Regeneron Pharmaceuticals
Verily & Kyverna Therapeutics
Kyverna Therapeutics & Elevate Bio
Kite & Arcellx
Galapagos & Thermo Fisher Scientific
Calibr-Skaggs & AbbVie
BioNTech & Autolus
Astellas Pharma & Kelonia Therapeutics
Fiocruz & Caring Cross
Cartherics & TiCARos
Bristol Myers Squibb
Chimeric Therapeutics & Cell Therapies
Nona Biosciences & Umoja Biopharma
Poseida Therapeutics & Roche
Takeda & Alloy Therapeutics
7. CAR-T MERGER & ACQUISITION (M&A) DEALS (29 TOTAL)
Descriptions M&A Deals in CAR-T Space, January 2015 to February 205
Cellular Biomedicine & Chinese PLA General Hospital
Gilead Sciences & Kite Pharma
Gilead Sciences & Cell Design Labs
Novartis & Endocyte
Bristol Myers Squibb & Celgene
Xenetic Biosciences & Scripps Research Institute
Astellas Pharma & Xyphos Biosciences
BioNTech & Neon Therapeutics
resTORbio & Adicet Bio
Century Therapeutics & Empirica Therapeutics
Celularity & GX Acquisition
Cellular Biomedicine & CBMG Merger Sub
Amgen & Five Prime Therapeutics
BioNTech & Kite
ImmPACT Bio & Kalthera
Kiromic Biopharma & InSilico Solutions
Allogene Therapeutics & Antion Biosciences
FUJIFILM Corporation & Atara Biotherapeutics
Galapagos & CellPoint/AboundBio
Atossa Therapeutics & Dynamic Cell Therapies
Kite & Tmunity Therapeutics
Janssen & Cellular Biomedicine
Mustang Bio & uBriGene Biosciences
Precision Biosciences & Imugene
Oxford Biomedica & Institut Merieux
Clade Therapeutics & Gadeta
Kyowa Kirin & Orchard Therapeutics
AstraZeneca & Gracell Biotechnologies
Ginkgo Bioworks & Modulus Therapeutics
8. PROFILES OF COMPANIES INCLUDED IN THIS REPORT
AdAlta Ltd.
Adicet Bio
AffyImmune Therapeutics, Inc
Allogene Therapeutics
Alpha Biopharma
Antion Biosciences
Arcellx, Inc.
Arsenal Biosciences, Inc
Astellas Pharma, Inc.
Atara Biotherapeutics
Autolus Therapeutics PLC
AvenCell Therapeutics, Inc
Beam Therapeutics
Bellicum Pharmaceuticals, Inc
Biosceptre
BioNTech SE
bluebird bio
Cargo Therapeutics
Caribou Biosciences, Inc.
Carina Biotech
CARsgen Therapeutics Holdings Limited
Cartherics Pty Ltd
Cellares
Cellectis
Cellular Biomedicine Group
Celularity, Inc
Celyad Oncology
Chengdu Usano Biotechnology Co., ltd. (Ucello)
Chimeric Therapeutics, Ltd
Clade Therapeutics
Coeptis Therapeutics, Inc.
CRISPR Therapeutics
Currus Biologics
CytoMed Therapeutics Ltd
Dynamic Cell Therapies, Inc
Elicera Therapeutics
Galapagos NV
Gracell Biotechnologies
EXUMA Biotech Corp
IASO Biotherapeutics
ImmPACT Bio
Inceptor Bio
Interius BioTherapeutics
Invectys, Inc
Juventas Cell Therapy, Ltd.
JW Therapeutics
Galapagos NV
Kite Pharma (Gilead)
Kyverna Therapeutics
Legend Biotech
Leucid Bio, Ltd
Luminary Therapeutics
Lupagen, Inc
MaxCyte, Inc
Minerva Biotechnologies
Mustang Bio, Inc
Noile-Immune Biotech
Novartis AG
OneChain Immunotherapeutics
Oncternal Therapeutics, Inc
OriCell Therapeutics
Oxford Biomedica PLC
Pepromene Bio, Inc
PersonGen Bio Therapeutics (Suzhou) Co., Ltd
Poseida Therapeutics, Inc.
Precigen, Inc
Precision BioSciences
Prescient Therapeutics
Simnova Biotherapeutics
SOTIO Biotech B.V.
TC BioPharm
Umoja Biopharma
Verismo Therapeutics, Inc.
Vor Biopharma
Wugen, Inc.
Xenetic Biosciences, Inc.
Xyphos Biosciences, Inc.
For more information about this report visit
About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
